Sai-Hong I. Ou, MD

Articles

Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLC

May 5th 2018

Sai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).